The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...

Novavax (NASDAQ:NVAX) shares fell ~3% in the premarket on Thursday after the company issued a clarification on an analyst ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $14.42 which represents a decrease of $-0.26 or -1.77% from the prior close of $14.68. The stock opened at $14.07 and touched a ...

Shares of Novavax Inc. NVAX shed 5.62% to $13.61 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...

The federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health ...

TORONTO — The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus ...

Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.

In a report released today, Roger Song from Jefferies maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of ...

It is still a thing." Health Canada also approved the protein-based Novavax vaccine (Nuvaxovid) last week. It's designed to target JN.1, which is the dominant lineage in Canada at the moment.